Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pneumonia, Hospital-Acquired Clear all
Completed No phase listed Observational

Clinician Ability to Predict the Presence of Nosocomial Pneumonia Based on Bronchoscopic Findings

NCT01904305
View directory record Official record
Conditions
Pneumonia
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Results available

An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia

NCT00502801
View directory record Official record
Conditions
Pneumonia, Bacterial Pneumonia, Ventilator-Associated Pneumonia, Infections, Nosocomial
Interventions
doripenem
Drug
Lead sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
24
States / cities
Palm Springs, California • San Francisco, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Jun 10, 2026, 1:54 AM EDT
Recruiting No phase listed Observational

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

NCT06746883
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
Non-interventional
Other
Lead sponsor
Innoviva Specialty Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Gainesville, Florida • Kansas City, Kansas • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)

NCT00148642
View directory record Official record
Conditions
Respiratory Failure
Interventions
silver salts coated endotracheal tube, uncoated endotracheal tube
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
San Diego, California • Oak Park, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia

NCT01021436
View directory record Official record
Conditions
Pneumonia
Interventions
Amikacin inhalation solution (BAY41-6551)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Birminghan, Alabama • Cincinnati, Ohio • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Jun 10, 2026, 1:54 AM EDT
Completed No phase listed Observational

Telavancin Observational Use Registry (TOUR)

NCT02288234
View directory record Official record
Conditions
Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection
Interventions
Vibativ
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

NCT00107952
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional

A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)

NCT01004445
View directory record Official record
Conditions
Pneumonia
Interventions
Amikacin (BAY41-6551), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Birmingham, Alabama • Melbourne, Florida • Albany, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

NCT04223752
View directory record Official record
Conditions
Nosocomial Pneumonia
Interventions
Ceftolozane/Tazobactam
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Orlando, Florida • Rochester, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

NCT04215991
View directory record Official record
Conditions
Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
3 Months to 17 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jun 10, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Aerosolized and Intravenous Colistin in Healthy Adults

NCT01863719
View directory record Official record
Conditions
Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions
Colistimethate sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 10, 2026, 1:54 AM EDT
Completed No phase listed Observational

Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit

NCT04700202
View directory record Official record
Conditions
Ventilator-associated Pneumonia, Hospital-acquired Pneumonia
Interventions
Observational
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
132 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Not applicable Interventional Results available

Effect of Angulus on Patient-elevation Compliance

NCT03496220
View directory record Official record
Conditions
Ventilator Adverse Event, Ventilator Associated Pneumonia, Hospital Acquired Condition, Hospital-acquired Pneumonia, Recumbency, Head-of-bed
Interventions
Angulus
Device
Lead sponsor
Angulus, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Cricoid Pressure Reduce the Risk of Aspiration?

NCT02058004
View directory record Official record
Conditions
Microaspiration, Acute Respiratory Distress Syndrome (ARDS), Hospital Acquired Pneumonia
Interventions
Cricoid pressure
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Jun 10, 2026, 1:54 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

NCT00080496
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Tigecycline, Imipenem, Cilastatin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
29
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Martinez, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Results available

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00084266
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid (Zyvox), vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
108
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Jun 10, 2026, 1:54 AM EDT
Completed No phase listed Observational

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

NCT01086397
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions
Urine sample collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

NCT03032380
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Meropenem, Linezolid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Results available

Strategies To Prevent Pneumonia 2 (SToPP2)

NCT00893763
View directory record Official record
Conditions
Infections, Hospital, Ventilator-Associated Pneumonia, Mechanical Ventilation Complication
Interventions
Pre-intubation CHX, Control
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Jun 10, 2026, 1:54 AM EDT